1-18 of 18
Karen Kelly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study

Available to Purchase
Philip C. Mack, Mary W. Redman, Hanna Tukachinsky, David E. Kozono, Katherine Minichiello, Konstantin H. Dragnev, Khaled A. Tolba, Joel W. Neal, Russell W. Madison, Saiama N. Waqar, Charu Aggarwal, Fred R. Hirsch, Jyoti D. Patel, Roy S. Herbst, Anne C. Chiang, Karen L. Reckamp, Karen Kelly, Hossein Borghaei, Jhanelle E. Gray, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-24-3658
Published: 11 July 2025
View articletitled, Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study
Open the PDF for Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study in another window
Includes: Supplementary data
Journal Articles

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Open Access
Nehal J. Lakhani, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A. Yap, Afshin Dowlati, Robert G. Maki, Susanna Ulahannan, Filipa Lynce, Karen Kelly, Stephen Williamson, Jyoti Malhotra, Shuquan Chen, Ana Gonzalez Ortiz, Vladimir Jankovic, Anne Paccaly, Sheila Masinde, Jayakumar Mani, Israel Lowy, Giuseppe Gullo, Tasha Sims, Glenn Kroog
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5601–5611.
https://doi.org/10.1158/1078-0432.CCR-23-3883
Published: 16 December 2024
View articletitled, First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Open the PDF for First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Open Access
Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose, Edgar Gonzalez-Kozlova, Mary W. Redman, Hong Chen, Ganiraju C. Manyam, Gayatri Kumar, Jianhua Zhang, Xingzhi Song, Rossana Lazcano, Mario L. Marques-Piubelli, Caddie Laberiano-Fernandez, Frank Rojas, Baili Zhang, Len Taing, Aashna Jhaveri, Jacob Geisberg, Jennifer Altreuter, Franziska Michor, James Provencher, Joyce Yu, Ethan Cerami, Radim Moravec, Kasthuri Kannan, Rajyalakshmi Luthra, Gheath Alatrash, Hsin-Hui Huang, Hui Xie, Manishkumar Patel, Kai Nie, Jocelyn Harris, Kimberly Argueta, James Lindsay, Roshni Biswas, Stephen Van Nostrand, Seunghee Kim-Schulze, Jhanelle E. Gray, Roy S. Herbst, Ignacio I. Wistuba, Scott Gettinger, Karen Kelly, Lyudmila Bazhenova, Sacha Gnjatic, J. Jack Lee, Jianjun Zhang, Cara Haymaker
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1655–1668.
https://doi.org/10.1158/1078-0432.CCR-23-0251
Published: 15 April 2024
View articletitled, Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Open the PDF for Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Available to Purchase
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, III, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3641–3649.
https://doi.org/10.1158/1078-0432.CCR-22-3947
Published: 15 September 2023
View articletitled, Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Open the PDF for Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Available to Purchase
Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3752–3760.
https://doi.org/10.1158/1078-0432.CCR-22-0741
Published: 01 September 2022
View articletitled, Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Open the PDF for Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403) in another window
Includes: Supplementary data
Journal Articles

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

Open Access
D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip B. Komarnitsky, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5781–5792.
https://doi.org/10.1158/1078-0432.CCR-21-0765
Published: 01 November 2021
View articletitled, Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
Open the PDF for Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Available to Purchase
Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View articletitled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Free
Edward S. Kim, Karen Kelly, Luis G. Paz-Ares, Pilar Garrido, Shadia Jalal, Daruka Mahadevan, Martin Gutierrez, Mariano Provencio, Eric Schaefer, Monte Shaheen, Erica L. Johnston, P. Kellie Turner, Siva Rama Prasad Kambhampati, Richard Beckmann, Anwar Hossain, William J. John, Jonathan W. Goldman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (22): 5543–5551.
https://doi.org/10.1158/1078-0432.CCR-18-0651
Published: 15 November 2018
View articletitled, Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Open the PDF for Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Free
Primo N. Lara, Jr, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4321–4326.
https://doi.org/10.1158/1078-0432.CCR-14-3281
Published: 30 September 2015
View articletitled, Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib
Open the PDF for Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib in another window
Journal Articles

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

Free
Benjamin K. Tomlinson, James A. Thomson, John S. Bomalaski, Monica Diaz, Taiwo Akande, Nichole Mahaffey, Tianhong Li, Mrinal P. Dutia, Karen Kelly, I-Yeh Gong, Thomas Semrad, David R. Gandara, Chong-Xian Pan, Primo N. Lara, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2480–2486.
https://doi.org/10.1158/1078-0432.CCR-14-2610
Published: 31 May 2015
View articletitled, Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors
Open the PDF for Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Free
Paul A. Bunn, Jr., Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, Samir E. Witta, Karen Kelly, Fred R. Hirsch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3652–3656.
https://doi.org/10.1158/1078-0432.CCR-06-0261
Published: 15 June 2006
View articletitled, Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Open the PDF for Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in another window
Journal Articles

The Role of Targeted Agents in Adjuvant Therapy for Non–Small Cell Lung Cancer

Free
Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 5027s–5029s.
https://doi.org/10.1158/1078-0432.CCR-05-9002
Published: 06 July 2005
View articletitled, The Role of Targeted Agents in Adjuvant Therapy for Non–Small Cell Lung Cancer
Open the PDF for The Role of Targeted Agents in Adjuvant Therapy for Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

Free
Samir E. Witta, Daniel L. Gustafson, A. Scott Pierson, Alexander Menter, Scott N. Holden, Michele Basche, Martha Persky, Cindy L. O’Bryant, Chan Zeng, Anna Baron, Michael E. Long, Amy Gibbs, Karen Kelly, Paul A. Bunn, Jr., Daniel C. Chan, Patrick Pallansch, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7229–7237.
https://doi.org/10.1158/1078-0432.CCR-03-0181
Published: 08 November 2004
View articletitled, A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Free
Christian Monnerat, Thierry Le Chevalier, Karen Kelly, Coleman K. Obasaju, Julie Brahmer, Silvia Novello, Takashi Nakamura, Astra M. Liepa, Laurence Bozec, Paul A. Bunn, Jr, David S. Ettinger
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5439–5446.
https://doi.org/10.1158/1078-0432.CCR-04-0218
Published: 24 August 2004
View articletitled, Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Open the PDF for Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer in another window
Journal Articles

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

Free
Martin J. Edelman, Joseph I. Clark, Kari Chansky, Kathy Albain, Nirmala Bhoopalam, Geoffrey R. Weiss, Jeffrey K. Giguere, Karen Kelly, John Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5022–5026.
https://doi.org/10.1158/1078-0432.CCR-04-0002
Published: 05 August 2004
View articletitled, Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel
Open the PDF for Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel in another window
Journal Articles

Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group

Free
Karen Kelly, Laura Lovato, Paul A. Bunn, Jr., Robert B. Livingston, Jeffrey Zangmeister, Sarah A. Taylor, Debasish Roychowdhury, John J. Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2325–2329.
Published: 01 August 2001
View articletitled, Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group
Open the PDF for Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group in another window
Journal Articles

A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer

Free
Karen Kelly, Nadine Mikhaeel-Kamel, Zhaoxing Pan, James Murphy, Sheila Prindiville, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3474–3479.
Published: 01 September 2000
View articletitled, A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer in another window
Journal Articles

A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer

Free
Karen Kelly, Zhaoxing Pan, Marie E. Wood, James Murphy, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (11): 3419–3424.
Published: 01 November 1999
View articletitled, A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer
Open the PDF for A Phase I Study of Paclitaxel, Etoposide, and Cisplatin in Extensive Stage Small Cell Lung Cancer in another window